VRX Is About To Implode

The day has come!!!! What goes around Fatboy...

 

2015 = more pressure = no sales as we have nothing except 2 person in marketing no samples or nothing in the pipeline as R&D was cut. We'll just have more cuts everyone

 

Let's hope you're wrong. Thousands of jobs are at stake

 

Let's hope so but I doubt it: latest article on VRX, no more acquisitions so more cuts very likely!

 

In partnership with activist investor Bill Ackman, the company made a hostile bid to purchase Botox-maker Allergan.

Valeant Pharmaceuticals is putting its acquisition growth strategy on hold in favor of reducing debt and boosting its stock price, according to Reuters.

Since 2008, Valeant has spent about $19 billion on 40 acquisitions. Now, the company will stem those purchases over the next two to three quarters to strengthen its financial fundamentals, sources told Reuters.

Valeant, in partnership with activist investor Bill Ackman, made a hostile bid to purchase Botox-maker Allergan AGN -0.50% . The offer failed last month, and now the Canada-based drugmaker is regrouping under a new strategic vision.

As Allergan fought off the company’s advances, it voiced concerns that Valeant’s underlying financial situation was not strong: It masked growth through its ongoing acquisitions, Allergan claimed. The California drugmaker eventually agreed to a $66 billion buyout by Actavis ACT -1.73% , successfully deflecting Valeant’s hostile offer.

Valeant VRX -3.22% has more than $16.3 billion in debt as of the end of September and has a junk rating, according to Moody’s. The drugmaker is hoping to improve its credit rating in order to better afford future purchases, sources told Reuters.

The regroup is a change from the norm–Valeant has aggressively pursued other drugmakers as a way to drive fast growth, and, for the most part, it’s worked.

Valeant’s market valuation has grown to more than $48 billion today from about $1 billion in 2008. CEO Mike Pearson has pushed for Valeant to become one of the world’s top five pharmaceutical companies by the end of 2016.

As it hunkers down, Valeant is rewarding shareholders with up to $2 billion in buybacks of senior notes, shares and other securities, the drugmaker announced last month.

 

As it hunkers down, Valeant is rewarding shareholders with up to $2 billion in buybacks of senior notes, shares and other securities, the drugmaker announced last month.


Typical, while the valued employees are cut!!!!!
MP has fucked us over again!!!!

 

If you stay, then you are admitting you like it.

 

Such negativity. Some prefer to complain that Valeant's pipeline is half-empty, but optimists will choose to think of it as half-full. Or at least one-fifth full. (Make that one-tenth full.)

Also, don't forget: with the huge, recent drop in jet fuel prices, Pearson is actually saving the company tons of money when he and his family make their frequent flights out of Teterboro on the private company jet. Now that, my friends, is what is called "leadership".

 

And you Obviously agree with shareholders being rewarded when employees are cut!!!
Fuckwit manager!

 

Whichever way we look at all this, it just ain't good!

 

Amen!

 

How big is the bomb gona be?

 

Nuclear

 

Pin has been pulled...

 

Don't say it's so, Bridgewater is about to blow up. Oh my, run. LOSER

 

I hope you left your name with security as there won't be much of you remaining to id.

 

There won't be much left of anything or anyone!

 

Two more lawsuits issued to Valeant today!
How's Pearson gona pay for this? Did I hear you say more cost cutting.... Maybe there's a goldmine under the office in Canada!

 

Trying to defend the undefendable is not gona work Mikey!

 

Exactly! And more lawsuits on the way.....better start digging Pearson!